Header

UZH-Logo

Maintenance Infos

Browse by Creators

Navigate back| Up a level
Export as
Number of items: 38.

Krähenbühl, Lukas; Goldinger, Simone M; Mangana, Joanna; Kerl, Katrin; Chevolet, Ines; Brochez, Liève; Horak, Christine; Levesque, Mitch; Dummer, Reinhard; Cheng, Phil F (2018). A Longitudinal Analysis of IDO and PDL1 Expression during Immune- or Targeted Therapy in Advanced Melanoma. Neoplasia, 20(2):218-225.

Braun, Ralph P; Mangana, Johanna; Goldinger, Simone M; French, Lars; Dummer, Reinhard; Marghoob, Ashfaq A (2017). Electrical impedance spectroscopy in skin cancer diagnosis. Dermatologic Clinics, 35(4):489-493.

Izar, Benjamin; Sharfman, William; Hodi, F Stephen; Lawrence, Donald; Flaherty, Keith T; Amaravadi, Ravi; Kim, Kevin B; Puzanov, Igor; Sosman, Jeffrey; Dummer, Reinhard; Goldinger, Simone M; Lam, Lyhping; Kakar, Shefali; Tang, Zhongwen; Krieter, Oliver; McDermott, David F; Atkins, Michael B (2017). A first-in-human phase I, multicenter, open-label, dose-escalation study of the oral RAF/VEGFR-2 inhibitor (RAF265) in locally advanced or metastatic melanoma independent from BRAF mutation status. Cancer Medicine, 6(8):1904-1914.

Frauchiger, Anna L; Brüggen, Marie-Charlotte; Goldinger, Simone M; Dummer, Reinhard (2017). Interstitial granulomatous dermatitis during talimogen laherparepvec treatment. Melanoma research, 27(4):400-401.

Mangana, Joanna; Cheng, Phil F; Kaufmann, Corina; Amann, Valerie C; Frauchiger, Anna L; Stögner, Viola; Held, Ulrike; von Moos, Roger; Michielin, Olivier; Braun, Ralph P; Levesque, Mitchell P; Goldinger, Simone M; Dummer, Reinhard (2017). Multicenter, real-life experience with checkpoint inhibitors and targeted therapy agents in advanced melanoma patients in Switzerland. Melanoma research, 27(4):358-368.

Murer, Carla; Kränzlin-Stieger, Pascale; French, Lars E; Dummer, Reinhard; Goldinger, Simone M (2017). Successful treatment with imatinib after nilotinib and ipilimumab in a c-kit-mutated advanced melanoma patient: a case report. Melanoma research, 27(4):396-398.

Nosrati, Adi; Tsai, Katy K; Goldinger, Simone M; Tumeh, Paul; Grimes, Barbara; Loo, Kimberly; Algazi, Alain P; Nguyen-Kim, Thi Dan Linh; Levesque, Mitchell; Dummer, Reinhard; Hamid, Omid; Daud, Adil (2017). Evaluation of clinicopathological factors in PD-1 response: derivation and validation of a prediction scale for response to PD-1 monotherapy. British Journal of Cancer, 116(9):1141-1147.

Dummer, Reinhard; Ramelyte, Egle; Levesque, Mitch; Goldinger, Simone M; Braun, Ralph P (2017). Critical aspects to achieve a high-quality melanoma clinic. Current Opinion in Oncology, 29(2):145-150.

Bossart, Simon; Thurneysen, Selina; Rushing, Elisabeth; Frontzek, Karl; Leske, Henning; Mihic‐Probst, Daniela; Nagel, Hannes W; Mangana, Johanna; Goldinger, Simone M; Dummer, Reinhard (2017). Case Report: Encephalitis, with Brainstem Involvement, Following Checkpoint Inhibitor Therapy in Metastatic Melanoma. The oncologist, 22(6):749-753.

Haueis, Silvia A; Kränzlin, Pascale; Mangana, Joanna; Cheng, Phil F; Urosevic-Maiwald, Mirjana; Braun, Ralph P; Levesque, Mitchell P; Dummer, Reinhard; Goldinger, Simone M (2017). Does the distribution pattern of brain metastases during BRAF inhibitor therapy reflect phenotype switching? Melanoma research, 27(3):231-237.

Zimmer, Lisa; Apuri, Susmitha; Eroglu, Zeynep; Kottschade, Lisa A; Forschner, Andrea; Gutzmer, Ralf; Schlaak, Max; Heinzerling, Lucie; Krackhardt, Angela M; Loquai, Carmen; Markovic, Svetomir N; Joseph, Richard W; Markey, Kelly; Utikal, Jochen S; Weishaupt, Carsten; Goldinger, Simone M; Sondak, Vernon K; Zager, Jonathan S; Schadendorf, Dirk; Khushalani, Nikhil I (2017). Ipilimumab alone or in combination with nivolumab after progression on anti-PD-1 therapy in advanced melanoma. European Journal of Cancer, 75:47-55.

Goldinger, Simone M. Melanoma - from Evolution to Revolution. 2017, University of Zurich, Faculty of Medicine.

Zimmer, Lisa; Goldinger, Simone M; Hofmann, Lars; Loquai, Carmen; Ugurel, Selma; Thomas, Ioannis; Schmidgen, Maria I; Gutzmer, Ralf; Utikal, Jochen S; Göppner, Daniela; Hassel, Jessica C; Meier, Friedegund; Tietze, Julia K; Forschner, Andrea; Weishaupt, Carsten; Leverkus, Martin; Wahl, Renate; Dietrich, Ursula; Garbe, Claus; Kirchberger, Michael C; Eigentler, Thomas; Berking, Carola; Gesierich, Anja; Krackhardt, Angela M; Schadendorf, Dirk; Schuler, Gerold; Dummer, Reinhard; Heinzerling, Lucie M (2016). Neurological, respiratory, musculoskeletal, cardiac and ocular side-effects of anti-PD-1 therapy. European Journal of Cancer, 60:210-225.

Henning, Benjamin; Stieger, Pascale; Kamarachev, Jivko; Dummer, Reinhard; Goldinger, Simone M (2016). Pyogenic granuloma in patients treated with selective BRAF inhibitors: another manifestation of paradoxical pathway activation. Melanoma research, 26(3):304-7.

Goldinger, Simone M; Gobbi Bischof, Sharon; Fink-Puches, Regina; Klemke, Claus-Detlev; Dréno, Brigitte; Bagot, Martine; Dummer, Reinhard (2016). Efficacy and safety of Apo866 in patients with refractory or relapsed cutaneous t-cell lymphoma: a phase 2 clinical trial. JAMA Dermatology, 152(7):837-839.

Goldinger, Simone M; Stieger, Pascale; Meier, Barbara; Micaletto, Sara; Contassot, Emmanuel; French, Lars E; Dummer, Reinhard (2016). Cytotoxic cutaneous adverse drug reactions during anti-PD-1 therapy. Clinical Cancer Research, 22(16):4023-4029.

Goldinger, Simone M; Blank, Christian U (2016). Malignes Melanom, gezielte Therapie und Immuntherapie – Der Weg zum Erfolg. Dermatologie Praxis:2-7.

Diem, Stefan; Keller, Fabienne; Rüesch, Reinhard; Maillard, Samia A; Speiser, Daniel E; Dummer, Reinhard; Siano, Marco; Urner-Bloch, Ursula; Goldinger, Simone M; Flatz, Lukas (2016). Pembrolizumab-triggered uveitis: an additional surrogate marker for responders in melanoma immunotherapy? Journal of Immunotherapy, 39(9):379-382.

Del Prete, Valerio; Chaloupka, Karla; Holzmann, David; Fink, Daniel; Levesque, Mitchell; Dummer, Reinhard; Goldinger, Simone M (2015). Noncutaneous melanomas: a single-center analysis. Dermatology, 232(1):22-29.

Van Allen, Eliezer M; Miao, Diana; Schilling, Bastian; Shukla, Sachet A; Blank, Christian; Zimmer, Lisa; Sucker, Antje; Hillen, Uwe; Geukes Foppen, Marnix H; Goldinger, Simone M; Utikal, Jochen; Hassel, Jessica C; Weide, Benjamin; Kaehler, Katharina C; Loquai, Carmen; Mohr, Peter; Gutzmer, Ralf; Dummer, Reinhard; Gabriel, Stacey; Wu, Catherine J; Schadendorf, Dirk; Garraway, Levi A (2015). Genomic correlates of response to CTLA4 blockade in metastatic melanoma. Science, 350(6257):207-211.

Matsushita, Shigeto; Krähenbühl, Lukas; Otsuka, Atsushi; Mihic-Probst, Daniela; Cheng, Phil; Dummer, Reinhard; Goldinger, Simone M (2015). Histological evaluation of a "residual" metastasis after ipilimumab therapy in a patient with advanced melanoma. Journal of Dermatology, 42(9):927-928.

Ribas, Antoni; Puzanov, Igor; Dummer, Reinhard; Schadendorf, Dirk; Hamid, Omid; Robert, Caroline; Hodi, F Stephen; Schachter, Jacob; Pavlick, Anna C; Lewis, Karl D; Cranmer, Lee D; Blank, Christian U; O'Day, Steven J; Ascierto, Paolo A; Salama, April K S; Margolin, Kim A; Loquai, Carmen; Eigentler, Thomas K; Gangadhar, Tara C; Carlino, Matteo S; Agarwala, Sanjiv S; Moschos, Stergios J; Sosman, Jeffrey A; Goldinger, Simone M; Shapira-Frommer, Ronnie; Gonzalez, Rene; Kirkwood, John M; Wolchok, Jedd D; Eggermont, Alexander; Li, Xiaoyun Nicole; Zhou, Wei; Zernhelt, Adriane M; Lis, Joy; Ebbinghaus, Scot; Kang, S Peter; Daud, Adil (2015). Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial. Lancet Oncology, 16(8):908-918.

Galliker, Nadja A; Murer, Carla; Kamarashev, Jivko; Dummer, Reinhard; Goldinger, Simone M (2015). Clinical observation of panniculitis in two patients with BRAF-mutated metastatic melanoma treated with a combination of a BRAF inhibitor and a MEK inhibitor. European Journal of Dermatology, 25(2):177-180.

Goldinger, Simone M; Rinderknecht, Jeannine; Dummer, Reinhard; Kuhn, Felix Pierre; Yang, Kuo-Hsiung; Lee, Lucy; Ayala, Ruben C; Racha, Jagdish; Geng, Wanping; Moore, David; Liu, Mei; Joe, Andrew K; Bazan, Selby Patricia Gil; Grippo, Joseph F (2015). A single-dose mass balance and metabolite-profiling study of vemurafenib in patients with metastatic melanoma. Pharmacology Research & Perspectives, 3(2):e00113.

Dummer, Reinhard; Goldinger, Simone M; Paulitschke, Verena; Levesque, Mitchell P (2015). Curing advanced melanoma by 2025. Current Opinion in Oncology, 27(2):125-127.

Johnson, Douglas B; et al; Goldinger, Simone M (2015). Acquired BRAF inhibitor resistance: A multicenter meta-analysis of the spectrum and frequencies, clinical behaviour, and phenotypic associations of resistance mechanisms. European Journal of Cancer, 51(18):2792-2799.

Mangana, Joanna; Cheng, Phil F; Schindler, Katja; Weide, Benjamin; Held, Ulrike; Frauchiger, Anna L; Romano, Emanuella; Kähler, Katharina C; Rozati, Sima; Rechsteiner, Markus; Moch, Holger; Michielin, Olivier; Garbe, Claus; Hauschild, Axel; Hoeller, Christoph; Dummer, Reinhard; Goldinger, Simone M (2015). Analysis of BRAF and NRAS mutation status in advanced melanoma patients treated with anti-CTLA-4 antibodies: association with overall survival? PLoS ONE, 10(10):e0139438.

Cheng, Phil F; Shakhova, Olga; Widmer, Daniel S; Eichhoff, Ossia M; Zingg, Daniel; Frommel, Sandra C; Belloni, Benedetta; Raaijmakers, Marieke Ig; Goldinger, Simone M; Santoro, Raffaella; Hemmi, Silvio; Sommer, Lukas; Dummer, Reinhard; Levesque, Mitchell P (2015). Methylation-dependent SOX9 expression mediates invasion in human melanoma cells and is a negative prognostic factor in advanced melanoma. Genome Biology, 16:42.

Dummer, Reinhard; Goldinger, Simone M; Widmer, Daniel; Dreier, Jil; Levesque, Mitchell P (2014). To B-(RAF) or not to be. Journal of Investigative Dermatology, 134(5):1200-1201.

Van Allen, Eliezer M; Wagle, Nikhil; Sucker, Antje; Treacy, Daniel J; Johannessen, Cory M; Goetz, Eva M; Place, Chelsea S; Taylor-Weiner, Amaro; Whittaker, Steven; Kryukov, Gregory V; Hodis, Eran; Rosenberg, Mara; McKenna, Aaron; Cibulskis, Kristian; Farlow, Deborah; Zimmer, Lisa; Hillen, Uwe; Gutzmer, Ralf; Goldinger, Simone M; Ugurel, Selma; Gogas, Helen J; Egberts, Friederike; Berking, Carola; Trefzer, Uwe; Loquai, Carmen; Weide, Benjamin; Hassel, Jessica C; Gabriel, Stacey B; Carter, Scott L; Getz, Gad; Garraway, Levi A; Schadendorf, Dirk (2014). The genetic landscape of clinical resistance to RAF inhibition in metastatic melanoma. Cancer Discovery, 4(1):94-109.

Goldinger, Simone M; Zimmer, Lisa; Schulz, Carsten; Ugurel, Selma; Hoeller, Christoph; Kaehler, Katharina C; Schadendorf, Dirk; Hassel, Jessica C; Becker, Juergen; Hauschild, Axel; Dummer, Reinhard (2014). Upstream mitogen-activated protein kinase (MAPK) pathway inhibition: MEK inhibitor followed by a BRAF inhibitor in advanced melanoma patients. European Journal of Cancer, 50(2):406-410.

Dummer, Reinhard; Goldinger, Simone M; Turtschi, Christian P; Eggmann, Nina B; Michielin, Olivier; Mitchell, Lada; Veronese, Luisa; Hilfiker, Paul René; Felderer, Lea; Rinderknecht, Jeannine D (2014). Vemurafenib in patients with BRAF(V600) mutation-positive melanoma with symptomatic brain metastases: Final results of an open-label pilot study. European Journal of Cancer, 50(3):611-621.

Raaijmakers, Marieke I G; Rozati, Sima; Goldinger, Simone M; Widmer, Daniel S; Dummer, Reinhard; Levesque, Mitchell P (2013). Melanoma immunotherapy: historical precedents, recent successes and future prospects. Immunotherapy, 5(2):169-182.

Rinderknecht, Jeannine D; Goldinger, Simone M; Rozati, Sima; Kamarashev, Jivko; Kerl, Katrin; French, Lars E; Dummer, Reinhard; Belloni, Benedetta (2013). RASopathic skin eruptions during vemurafenib therapy. PLoS ONE, 8(3):e58721.

Voskens, Caroline J; Goldinger, Simone M; Loquai, Carmen; Robert, Caroline; Kaehler, Katharina C; Berking, Carola; Bergmann, Tanja; Bockmeyer, Clemens L; Eigentler, Thomas; Fluck, Michael; Garbe, Claus; Gutzmer, Ralf; Grabbe, Stephan; Hauschild, Axel; Hein, Rüdiger; Hundorfean, Gheorghe; Justich, Armin; Keller, Ullrich; Klein, Christina; Mateus, Christine; Mohr, Peter; Paetzold, Sylvie; Satzger, Imke; Schadendorf, Dirk; Schlaeppi, Marc; Schuler, Gerold; Schuler-Thurner, Beatrice; Trefzer, Uwe; Ulrich, Jens; Vaubel, Julia; von Moos, Roger; Weder, Patrik; Wilhelm, Tabea; Göppner, Daniela; Dummer, Reinhard; Heinzerling, Lucie M (2013). The price of tumor control: an analysis of rare side effects of anti-CTLA-4 therapy in metastatic melanoma from the ipilimumab network. PLoS ONE, 8(1):e53745.

Zimmer, Lisa; Hillen, Uwe; Livingstone, Elisabeth; Lacouture, Mario E; Busam, Klaus; Carvajal, Richard D; Egberts, Friederike; Hauschild, Axel; Kashani-Sabet, Mohammed; Goldinger, Simone M; Dummer, Reinhard; Long, Georgina V; McArthur, Grant; Scherag, André; Sucker, Antje; Schadendorf, Dirk (2012). Atypical Melanocytic Proliferations and New Primary Melanomas in Patients With Advanced Melanoma Undergoing Selective BRAF Inhibition. Journal of Clinical Oncology, 30(19):2375-2383.

Belloni, Benedetta; Schönewolf, Nicola; Rozati, Sima; Goldinger, Simone M; Dummer, Reinhard (2012). Cutaneous drug eruptions associated with the use of new oncological drugs. Chemical Immunology and Allergy, 97:191-202.

Goldinger, Simone M; Dummer, Reinhard; Baumgaertner, Petra; Mihic-Probst, Daniela; Schwarz, Katrin; Hammann-Haenni, Anya; Willers, Joerg; Geldhof, Christine; Prior, John O; Kündig, Thomas M; Michielin, Olivier; Bachmann, Martin F; Speiser, Daniel E (2012). Nano-particle vaccination combined with TLR-7 and -9 ligands triggers memory and effector CD8⁺ T-cell responses in melanoma patients. European Journal of Immunology, 42(11):3049-3061.

This list was generated on Wed Aug 22 07:39:57 2018 CEST.